RU2016134258A - Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами - Google Patents

Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами Download PDF

Info

Publication number
RU2016134258A
RU2016134258A RU2016134258A RU2016134258A RU2016134258A RU 2016134258 A RU2016134258 A RU 2016134258A RU 2016134258 A RU2016134258 A RU 2016134258A RU 2016134258 A RU2016134258 A RU 2016134258A RU 2016134258 A RU2016134258 A RU 2016134258A
Authority
RU
Russia
Prior art keywords
drug conjugate
conjugate
dual drug
absent
component
Prior art date
Application number
RU2016134258A
Other languages
English (en)
Other versions
RU2016134258A3 (ru
Inventor
Чжэньвэй Мяо
Ган ЧЭНЬ
Тун Чжу
Алишер Б. КХАСАНОВ
Юйфын Хун
Александр ХУХОЛОВСКИЙ
Хун ЧЖАНЬ
Original Assignee
Сорренто Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сорренто Терапьютикс Инк. filed Critical Сорренто Терапьютикс Инк.
Publication of RU2016134258A publication Critical patent/RU2016134258A/ru
Publication of RU2016134258A3 publication Critical patent/RU2016134258A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (44)

1. Двойной конъюгат лекарственных средств, включающий структуру Формулы I:
Figure 00000001
(I)
или его фармацевтически приемлемая соль,
где:
A является направляющим белком;
каждый D 1 может быть выбран независимо, где каждый D 1 включает активное вещество;
каждый L 1 независимо является линкером, включающим по меньшей мере один атом N (азота);
каждый D 2 выбран независимо, где каждый D 2 включает активное вещество;
каждый L 2 независимо является линкером;
E-компонент является необязательно замещенным гетероарилом или необязательно замещенным гетероциклилом;
каждый L 3 является необязательно замещенным C1-C6 алкилом, или каждый L 3 отсутствует, когда L 3 отсутствует, сера непосредственно связана с E-компонентом; и
каждый L 4 является необязательно замещенным C1-C6 алкилом, или каждый L 4 отсутствует, когда L 4 отсутствует, сера непосредственно связана с E-компонентом;
m является 1, 2, 3, 4, 5, 6, 7, 8, 9 или 10; и
n является 1, 2, 3, 4, 5, 6, 7, 8, 9 или 10.
2. Двойной конъюгат лекарственных средств по п. 1, где E-компонент включает фрагмент, выбранный из группы, состоящей из:
Figure 00000002
3. Двойной конъюгат лекарственных средств по п. 1, где L 3 представляет собой -(CH2)-; и L 4 представляет собой -(CH2)-.
4. Двойной конъюгат лекарственных средств по п. 1, где L 3 отсутствует; и L 4 отсутствует.
5. Двойной конъюгат лекарственных средств по п. 1, где:
Figure 00000003
является:
Figure 00000004
6. Двойной конъюгат лекарственных средств по п. 1, где L 1 включает
Figure 00000005
, где X 1 представляет собой N (азот) или CH; Y 1 представляет собой N (азот) или CH; и p является 0, 1 или 2.
7. Конъюгат активного вещества по п. 6, где L1 включает:
Figure 00000006
8. Двойной конъюгат лекарственных средств по п. 1, где каждый D 1 независимо выбран из группы, состоящей из тубулин-связывающих средств, ДНК-алкилирующих средств, ДНК-интеркалятора, ингибиторов ферментов, иммуномодуляторов, пептидов и нуклеотидов.
9. Двойной конъюгат лекарственных средств по п. 1, где каждый D 2 независимо выбран из группы, состоящей из тубулин-связывающих средств, ДНК-алкилирующих средств, ДНК-интеркалятора, ингибиторов ферментов, иммуномодуляторов, пептидов и нуклеотидов.
10. Двойной конъюгат лекарственных средств по п. 1, где L 1 или L 2 включает -(CH2)n-, где n является 1, 2, 3, 4, 5, 6, 7, 8, 9 или 10.
11. Двойной конъюгат лекарственных средств по п. 1, где L 1 или L 2 включает -(CH2CH2O)n-, где n является 1, 2, 3, 4, 5, 6, 7, 8, 9 или 10.
12. Двойной конъюгат лекарственных средств по п. 1, где компонент A включает по меньшей мере один модифицированный остаток L-аланина, который связан по меньшей мере с одной серой в L 1 .
13. Двойной конъюгат лекарственных средств по п. 1, где каждый
Figure 00000007
является:
Figure 00000008
Figure 00000009
где G является -NH-.
14. Двойной конъюгат лекарственных средств по п. 1, где каждый
Figure 00000010
является:
Figure 00000011
Figure 00000012
Figure 00000013
15. Двойной конъюгат лекарственных средств по п. 1, где структура выбрана из группы, состоящей из:
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
или их фармацевтически приемлемой соли.
RU2016134258A 2013-10-15 2014-10-15 Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами RU2016134258A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361891310P 2013-10-15 2013-10-15
US61/891,310 2013-10-15
PCT/US2014/060750 WO2015057876A1 (en) 2013-10-15 2014-10-15 Drug-conjugates with a targeting molecule and two different drugs

Publications (2)

Publication Number Publication Date
RU2016134258A true RU2016134258A (ru) 2018-02-28
RU2016134258A3 RU2016134258A3 (ru) 2018-06-25

Family

ID=52810213

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016134258A RU2016134258A (ru) 2013-10-15 2014-10-15 Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами

Country Status (10)

Country Link
US (2) US10836821B2 (ru)
EP (1) EP3057610B1 (ru)
CN (1) CN106132431A (ru)
AU (1) AU2014337317A1 (ru)
CA (1) CA2934030A1 (ru)
IL (1) IL246218A0 (ru)
RU (1) RU2016134258A (ru)
SG (1) SG11201604879QA (ru)
WO (1) WO2015057876A1 (ru)
ZA (1) ZA201604375B (ru)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2013173393A1 (en) 2012-05-15 2013-11-21 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
EP3590922A1 (en) 2013-03-15 2020-01-08 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2015038649A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
CN106132431A (zh) 2013-10-15 2016-11-16 索伦托治疗有限公司 具有靶向分子和两种不同药物的药物偶联物
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
CN106459162A (zh) 2013-12-27 2017-02-22 酵活有限公司 Var2csa‑药物偶联物
WO2015116774A1 (en) 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015134464A2 (en) 2014-03-03 2015-09-11 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3131586A4 (en) 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
CN113416229A (zh) 2014-09-17 2021-09-21 酵活有限公司 细胞毒性和抗有丝***化合物、及其使用方法
JP6871858B2 (ja) * 2015-01-28 2021-05-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート
WO2017025057A1 (en) 2015-08-11 2017-02-16 Coherent Biopharma Multi-ligand drug conjugates and uses thereof
EP3377112A4 (en) 2015-11-18 2019-06-12 Sorrento Therapeutics, Inc. CHEMICALLY BLOCKED BISPECIFIC ANTIBODIES
CN106729743B (zh) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
CN115645544A (zh) * 2016-05-31 2023-01-31 索伦托药业有限公司 具有鹅膏毒肽的衍生物作为药物的抗体药物缀合物
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
SG10202107429WA (en) 2017-01-06 2021-08-30 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
CN108285487B (zh) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
AR111781A1 (es) * 2017-05-10 2019-08-21 Sanofi Sa Ligadores peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico
JP2020524156A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬を含む併用療法
EP3641647A4 (en) 2017-06-20 2021-05-05 Madrigal Pharmaceuticals, Inc. TARGETED THERAPEUTICS
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
WO2019034177A1 (zh) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
MX2020003596A (es) 2017-10-04 2020-07-22 Avidity Biosciences Inc Composiciones de acido nucleico-polipeptido y usos de las mismos.
CA3083526A1 (en) 2017-12-06 2019-06-13 Andrew John Geall Compositions and methods of treating muscle atrophy and myotonic dystrophy
WO2019246445A1 (en) 2018-06-20 2019-12-26 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
SG11202106593UA (en) 2018-12-21 2021-07-29 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020245229A1 (en) * 2019-06-03 2020-12-10 Synaffix B.V. Acetal-based cleavable linkers
EP3980436A4 (en) 2019-06-06 2023-12-20 Avidity Biosciences, Inc. NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
AU2020287880A1 (en) 2019-06-06 2022-01-20 Avidity Biosciences, Inc. UNA amidites and uses thereof
US11744876B2 (en) 2019-06-10 2023-09-05 Sutro Biopharma, Inc. Immunomodulator antibody drug conjugates and uses thereof
EP3797796A4 (en) 2019-08-07 2021-10-27 MabPlex International Co., Ltd. ANTIBODY INGREDIENT CONJUGATES AND USES THEREOF
JP2023537798A (ja) 2020-03-19 2023-09-06 アビディティー バイオサイエンシーズ，インク． 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
US11446387B2 (en) 2020-03-27 2022-09-20 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
CN113941007B (zh) * 2020-07-16 2024-06-07 成都科岭源医药技术有限公司 一种串联的双药物链接组装单元及其应用
CN115192731B (zh) * 2021-04-12 2023-09-26 中国科学院上海有机化学研究所 一种抗体药物偶联物的制备方法
CN114106088A (zh) * 2021-04-28 2022-03-01 联宁（苏州）生物制药有限公司 基于溴甲基吡嗪的药物偶联物及adc
EP4370555A1 (en) 2021-07-13 2024-05-22 TrueBinding, Inc. Methods of preventing protein aggregation
WO2023000131A1 (zh) * 2021-07-19 2023-01-26 烟台迈百瑞国际生物医药股份有限公司 一种负载双毒素的抗体药物偶联物及其应用
AU2022345098A1 (en) 2021-09-16 2024-04-04 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2023122347A2 (en) 2021-12-23 2023-06-29 Mirecule, Inc. Compositions for delivery of polynucleotides
CN117085144A (zh) * 2022-05-18 2023-11-21 成都百利多特生物药业有限责任公司 配体药物偶联物及其应用
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2173150C (en) 1993-10-01 2004-11-30 Kyoichi Sakakibara Novel peptide derivatives
WO2002055530A2 (en) 2000-10-25 2002-07-18 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
ES2556641T3 (es) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
AU2003275126A1 (en) * 2002-09-20 2004-04-08 Wyeth Holdings Corporation Hemiasterlin derivatives for treating resistant tumors
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2006132670A2 (en) * 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
CA2594636A1 (en) 2005-01-31 2006-08-10 Genentech, Inc. Anti-ephb2 antibodies and methods using same
MX2008009956A (es) * 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
US20110263650A1 (en) 2007-07-20 2011-10-27 Helmholtz-Zentrum Für Infektions-Forschung Gmbh Tubulysin D Analogues
EP2303332B1 (en) 2008-07-15 2014-12-31 Genentech, Inc. Anthracycline conjugates, process for their preparation and their use as antitumor compounds
EP2174947A1 (en) 2008-09-25 2010-04-14 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
CA3159253A1 (en) 2009-01-09 2010-07-15 Seagen Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
EA201201120A1 (ru) 2010-02-08 2013-03-29 Эдженсис, Инк. Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 161p2f10b
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
EP2409983A1 (en) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Tubulysin analogues
JP5933562B2 (ja) 2010-09-29 2016-06-15 シアトル ジェネティックス， インコーポレイテッド Ｎ−カルボキシアルキル−アウリスタチンおよびその使用
EP2646456B1 (en) 2010-12-02 2015-01-21 Nerviano Medical Sciences S.r.l. Process for the preparation of morpholinyl anthracycline derivatives
JP6581774B2 (ja) 2011-05-27 2019-09-25 アンブルックス, インコーポレイテッドAmbrx, Inc. 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法
EP3170821B1 (en) 2011-05-27 2021-09-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
BR112013032928A2 (pt) 2011-06-21 2017-01-24 Immunogen Inc "derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos"
KR20140139480A (ko) 2011-12-05 2014-12-05 이제니카 바이오테라퓨틱스, 인크. 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
WO2013173393A1 (en) 2012-05-15 2013-11-21 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
NZ703298A (en) 2012-06-07 2016-04-29 Ambrx Inc Prostate-specific membrane antigen antibody drug conjugates
NZ703581A (en) 2012-06-19 2016-09-30 Ambrx Inc Anti-cd70 antibody drug conjugates
EP2869847B1 (en) 2012-07-09 2017-12-06 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
CN106132431A (zh) 2013-10-15 2016-11-16 索伦托治疗有限公司 具有靶向分子和两种不同药物的药物偶联物
JP6871858B2 (ja) 2015-01-28 2021-05-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート
US20170224835A1 (en) 2015-02-06 2017-08-10 Sorrento Therapeutics, Inc. Antibody Drug Conjugates

Also Published As

Publication number Publication date
US20150105540A1 (en) 2015-04-16
IL246218A0 (en) 2016-11-30
WO2015057876A8 (en) 2016-11-10
US11987622B2 (en) 2024-05-21
EP3057610A1 (en) 2016-08-24
US10836821B2 (en) 2020-11-17
SG11201604879QA (en) 2016-07-28
AU2014337317A1 (en) 2016-09-15
EP3057610A4 (en) 2017-07-05
CA2934030A1 (en) 2015-04-23
US20210017274A1 (en) 2021-01-21
EP3057610B1 (en) 2021-09-22
CN106132431A (zh) 2016-11-16
WO2015057876A1 (en) 2015-04-23
ZA201604375B (en) 2019-04-24
RU2016134258A3 (ru) 2018-06-25

Similar Documents

Publication Publication Date Title
RU2016134258A (ru) Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами
JP2015518831A5 (ru)
JP2019514877A5 (ru)
NZ715646A (en) Antibody drug conjugates
RU2019119442A (ru) Новый коньюгат аманитина
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
RU2017139121A (ru) Композиции для модулирования экспрессии c9orf72
JP2014534220A5 (ru)
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
EA201000614A1 (ru) Производные пурина как лиганды аденозинового рецептора а
JP2014508804A5 (ru)
HRP20220123T1 (hr) Citotoksični i antimitotički spojevi, te postupci njihove uporabe
MX2019005671A (es) Sustancias para direccionar diversos organos o tejidos seleccionados.
Brucoli et al. Novel C8-linked pyrrolobenzodiazepine (PBD)–heterocycle conjugates that recognize DNA sequences containing an inverted CCAAT box
SG194717A1 (en) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants againstischemic brain damage and for treatment of pain
EA201270266A1 (ru) Гетероциклические соединения
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
AR083383A1 (es) Sales de antagonistas de ccr3 de arilsulfonamida
BR112014002734A2 (pt) "ligantes de receptor de estrogênio, composição farmacêutica que os compreende e usos dos mesmos"
CA2954175A1 (en) Compositions and methods to improve adoptive cell therapies
MX2013013146A (es) Inhibidores dimericos de alta afinidad de psd-95 como neuroprotectores eficientes contra daño isquemico cerebral y para el tratamiento de dolor.
JP2014515354A5 (ru)
JP2020040998A5 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20181009